Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1D Receptor Ligands with Improved Pharmacokinetic Profiles
- 21 May 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (12) , 2087-2104
- https://doi.org/10.1021/jm981133m
Abstract
It has previously been reported that a 3-(3-(piperazin-1-yl)propyl)indole series of 5-HT1D receptor ligands have pharmacokinetic advantages over the corresponding 3-(3-(piperidin-1-yl)propyl)indole series and that the reduced pKa of the piperazines compared to the piperidines may be one possible explanation for these differences. To investigate this proposal we have developed versatile synthetic strategies for the incorporation of fluorine into these ligands, producing novel series of 4-fluoropiperidines, 3-fluoro-4-aminopiperidines, and both piperazine and piperidine derivatives with one or two fluorines in the propyl linker. Ligands were identified which maintained high affinity and selectivity for the 5-HT1D receptor and showed agonist efficacy in vitro. The incorporation of fluorine was found to significantly reduce the pKa of the compounds, and this reduction of basicity was shown to have a dramatic, beneficial influence on oral absorption, although the effect on oral bioavailability could not always be accurately predicted.Keywords
This publication has 24 references indexed in Scilit:
- Enhancement of Oral Absorption in Selective 5-HT1DReceptor Agonists: Fluorinated 3-[3-(Piperidin-1-yl)propyl]indolesJournal of Medicinal Chemistry, 1998
- Selective, Orally Active 5-HT1D Receptor Agonists as Potential Antimigraine AgentsJournal of Medicinal Chemistry, 1997
- 5‐HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5‐HT and sumatriptan with rizatriptan and L‐741,519British Journal of Clinical Pharmacology, 1996
- Pilot Study of MK-462 in MigraineCephalalgia, 1996
- Inhibition of the Trigemino-Vascular System with 5-HT1D Agonist Drugs: Selectively Targeting Additional Sites of ActionEuropean Neurology, 1996
- Cardiovascular Adverse Reactions to SumatriptanCNS Drugs, 1995
- Treatment of the migraine attackCurrent Opinion in Neurology, 1994
- Protonated 3-fluoropiperidines: an unusual fluoro directing effect and a test for quantitative theories of solvationJournal of the American Chemical Society, 1993
- SumatriptanDrugs, 1992
- Specific enolates from .alpha.-amino ketonesThe Journal of Organic Chemistry, 1980